Ligand Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44%
Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences
Read more at globenewswire.com
